Gilead Sciences, Inc.
Gilead Announces Two-Year Data from Pivotal Phase III Studies Evaluating Viread for Chronic Hepatitis B
Published in Health Business Week, November 21st, 2008
Gilead Sciences, Inc. (Nasdaq:GILD) announced the presentation of two-year (96-week) data from two Phase III pivotal clinical trials, Studies 102 and 103, evaluating the safety and efficacy of once-daily Viread(R) (tenofovir disoproxil fumarate) among adult patients with chronic hepatitis B virus (HBV) infection. These data will be presented during oral sessions at the annual meeting of the American Association for the Study of Liver Diseases (The Liver Meeting 2008) being held this week in San Francisco (October 31-November 4).
Studies 102 and 103 will evaluate treatment with Viread for up to eight years among patients with HBeAg-negative and HBeAg-positive chronic...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
Source: Health Business Week (2008-11-21)
More Articles from Health Business Week
- 19 Recordings/RCA Records
David Cook Celebrates the Release of His Self-Titled Debut Album on 11/18 With a Special Fan Only Performance in NYC - 3DIcon Corporation
3DIcon's CSpace 3D Imaging System Wins Technology of the Week Award - 3i Group
3i Group - Half Year Results - 3M
3M and Illinois Tool Works Settle Suit over Patent Infringement - 3SBio Inc.
3SBio Inc. Announces Preliminary Third Quarter 2008 Results - 99 Cents Only Stores
99 Cents Only Stores Will Sell 9 Apple iPod Nanos for Only 99 Cents Each to Celebrate the Grand Opening of Its Newest 99 Cents Only Stores on Thursday, November 6th, in El Cajon, California - More from this issue of Health Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
